Drugs / TQB3019
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06943677 | May 2025 → Dec 2027 expected | cancer | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2025-12-25 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Regulatory 中国生物制药2025年18款1类新药首次获批临床，全球化研发体系再深化 cttq.com ↗
2025年，中国生物制药共有3款PROTAC新药首次获得临床批准。 |
| 2025-04-27 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Results 科研实力获国际认可！正大天晴2款创新药临床前研究亮相2025 AACR cttq.com ↗
临床前研究[2]显示，TQB3019对多种耐药突变（包括共价抑制剂的耐药突变C481X及非共价抑制剂的耐药突变T474I、L528W等）展现出广谱抑制活性，具有解决BTK抑制剂获得性耐药问题的潜力。 |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-12-25 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 中国生物制药2025年18款1类新药首次获批临床，全球化研发体系再深化 cttq.com ↗ |
| 2025-04-27 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 科研实力获国际认可！正大天晴2款创新药临床前研究亮相2025 AACR cttq.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TQB3019 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06943677 ↗ |
| Route | Oral | “take TQB3019 capsules orally” NCT06943677 ↗ |